Trials / Withdrawn
WithdrawnNCT03240393
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
Phase II Multicenter 3-cohort Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received 1 or 2 Prior Lines of Systemic Therapy for Advanced/Metastatic Disease
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult Chinese patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INC280 | cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations |
Timeline
- Start date
- 2018-07-31
- Primary completion
- 2021-10-26
- Completion
- 2021-10-26
- First posted
- 2017-08-07
- Last updated
- 2018-07-26
Source: ClinicalTrials.gov record NCT03240393. Inclusion in this directory is not an endorsement.